MARKET

HUGE

HUGE

FSD Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.830
0.000
0.00%
Pre Market: 1.900 +0.07 +3.83% 06:52 12/04 EST
OPEN
1.850
PREV CLOSE
1.830
HIGH
1.850
LOW
1.740
VOLUME
1.16K
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
1.280
MARKET CAP
35.07M
P/E (TTM)
-0.4054
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) ("FSD Pharma" or the "Company") today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR.
Business Wire · 11/12 22:00
FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) ("FSD Pharma" or the "Company") today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR.
BusinessWire · 11/12 19:00
FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering
FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company ("Shares") and warrants to purchase 3,454,543 Shares (collectively, the "Securities") at a purchase price of US$2.20 per Share in a registered direct offering. The warrants have an exercise price of US$2.60 per Share, are immediately exercisable and expire five years from the date of issuance.
BusinessWire · 10/21 11:30
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the "FSD201 COVID-19 Trial"). The company is expected to start dosing patients in October 2020. We believe FSD201 may have the potential to address the over-exuberant inflammatory response characterized by COVID-19 infection that may lead to a cytokine storm and ultimately death.
BusinessWire · 10/05 11:30
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
\\- FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients TORONTO, ON / ACCESSWIRE / September 28, 2020 / FSD Pharma Inc.
ACCESSWIRE · 09/28 07:30
Thinking about buying stock in Aimmune Therapeutics, FSD Pharma, Amarin Corp, Trevena Inc, or American Airlines?
NEW YORK , Aug. 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AIMT, HUGE, AMRN, TRVN, and AAL.
PR Newswire · 08/31 13:31
FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19
- The study is expected to be conducted at 25-30 hospitals in North America -
ACCESSWIRE · 08/31 06:40
HUGE.CN: FSD Pharmas FSDs Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA.
By Steven Ralston, CFA CSE:HUGE.CN | NASDAQ:HUGE READ THE FULL HUGE.CN RESEARCH REPORT FSD Pharma (CSE:HUGE.CN) (NASDAQ:HUGE) has evolved into a specialty, biotech pharmaceutical R&D company as management advances its strategic objective of developing, over time, a pipeline of FDA-approved synthetic
Zacks Small Cap Research · 08/20 10:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HUGE. Analyze the recent business situations of FSD Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HUGE stock price target is 11.05 with a high estimate of 12.01 and a low estimate of 10.10.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 128.80K
% Owned: 0.67%
Shares Outstanding: 19.16M
TypeInstitutionsShares
Increased
3
41.52K
New
7
56.38K
Decreased
3
1.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Co-Chairman/Chief Executive Officer/Chief Compliance Officer/Executive Director
Raza Bokhari
Co-Chairman/Executive Director
Anthony Durkacz
President/Director
Zeeshan Saeed
Chief Financial Officer
Donal Carroll
Vice President
Sandra Lottes
Other
Shahzad Shah
Director
Larry Kaiser
Independent Director
Stephen Buyer
Independent Director
Robert Ciaruffoli
Independent Director
James Datin
Independent Director
Gerald Goldberg
Independent Director
David Urban
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HUGE
FSD Pharma Inc is a Canada-based company engaged in the cultivation of cannabis. The Company through its wholly owned subsidiary, FV Pharma, operates as an authorized licensed producer of cannabis for medical purposes (ACMPR). In addition, the Company also owns stakes in Canara, which specializes in indoor cultivation.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of FSD Pharma Inc stock information, including NASDAQ:HUGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HUGE stock methods without spending real money on the virtual paper trading platform.